Ingredient or product comparison
Topical vs Injectable GHK-Cu: Choosing Your Route
The delivery method determines which benefits you access. This distinction trips up many new users who assume a serum delivers the same results as an injection. Penetration Epidermis and upper dermis only Systemic distribution Best for Skin rejuvenation, fine
This source-based comparison does not add ratings or recommend a winner.
- The delivery method determines which benefits you access. This distinction trips up many new users who assume a serum delivers the same results as an injection.
- Penetration
- Epidermis and upper dermis only
- Systemic distribution
- Best for
- Skin rejuvenation, fine lines, surface wounds
- Gene modulation, systemic anti-aging, deep tissue repair
- Concentration
- 0.01-1% in formulation
- 1-2 mg/day reconstituted
- Onset
- 4-8 weeks for visible skin changes
- 2-4 weeks for anti-inflammatory effects
- PubMed evidence
- Multiple human skin trials
- Animal studies, in vitro genomic data
- Combination
- Pairs well with microneedling
- Pairs well with BPC-157, TB-500
- Side effects
- Rare; mild irritation in sensitive skin
- Injection site redness, mild stinging
- Topical GHK-Cu cannot reach deep tissues, joints, or organs. The stratum corneum blocks most peptide absorption. Microneedling partially solves this by creating temporary channels, but penetration remains limited to the dermis. For systemic gene modulation and anti-inflammatory effects, injection is the only validated route.
- Injectable GHK-Cu delivers the peptide to the bloodstream, where it reaches tissues throughout the body. This is the route that corresponds to the genomic studies showing 4,000+ gene modulation. Standard protocol: 1-2 mg/day subcutaneously, cycled 4-8 weeks on and 4 weeks off. For reconstitution instructions, see how to reconstitute GHK-Cu. For injection frequency guidance, see the GHK-Cu injection frequency guide.